Correlation Between Tel Aviv and BioLight Life

Can any of the company-specific risk be diversified away by investing in both Tel Aviv and BioLight Life at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tel Aviv and BioLight Life into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tel Aviv 35 and BioLight Life Sciences, you can compare the effects of market volatilities on Tel Aviv and BioLight Life and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tel Aviv with a short position of BioLight Life. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tel Aviv and BioLight Life.

Diversification Opportunities for Tel Aviv and BioLight Life

0.78

Correlation Coefficient

Tel Aviv  BioLight Life

Poor diversification

The 3 months correlation between Tel and BioLight is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Tel Aviv 35 and BioLight Life Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioLight Life Sciences and Tel Aviv is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tel Aviv 35 are associated (or correlated) with BioLight Life. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioLight Life Sciences has no effect on the direction of Tel Aviv i.e., Tel Aviv and BioLight Life go up and down completely randomly.

Pair Corralation between Tel Aviv and BioLight Life

Assuming the 90 days trading horizon Tel Aviv is expected to generate 5.66 times less return on investment than BioLight Life. But when comparing it to its historical volatility, Tel Aviv 35 is 2.73 times less risky than BioLight Life. It trades about 0.08 of its potential returns per unit of risk. BioLight Life Sciences is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  54,000  in BioLight Life Sciences on December 30, 2024 and sell it today you would earn a total of  13,100  from holding BioLight Life Sciences or generate 24.26% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Tel Aviv 35  vs.  BioLight Life Sciences

Pair Trading with Tel Aviv and BioLight Life

The main advantage of trading using opposite Tel Aviv and BioLight Life positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tel Aviv position performs unexpectedly, BioLight Life can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioLight Life will offset losses from the drop in BioLight Life's long position.

The idea behind Tel Aviv 35 and BioLight Life Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.